|Over a week ago|
INmune Bio 2.174M share Spot Secondary priced at $10.00 » 09:1607/1607/16/20
BTIG acted as sole book…
BTIG acted as sole book running manager for the offering.
INmune Bio announces offering of common stock, no amount given » 16:1207/1507/15/20
INmune Bio announced that…
INmune Bio announced that it has commenced an underwritten public offering of shares of common stock. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. BTIG is acting as the sole book-running manager for the offering.
INmune Bio price target raised to $26 from $13 at Roth Capital » 10:0807/1407/14/20
Roth Capital analyst…
Roth Capital analyst Jonathan Aschoff raised the firm's price target on INmune Bio to $26 from $13 and keeps a Buy rating on the shares after interim results from a Phase 1b trial demonstrated that Xpro1595 can reduce neuroinflammation in patients with Alzheimer's disease. The analyst, who said he is "highly encouraged" by the extent of neuroinflammation reduction as measured by change in white matter free water via MRI, cautioned investors that "it is still too early to make sweeping conclusions about likely cognitive improvements in the overall AD population."
Fly Intel: Pre-market Movers » 09:0207/1407/14/20
KPTI, TSLA, FIT, HBI, INMB, EQ, VRCA, SPOT, OSMT, JPM, C, WFC
Check out this morning's…
Fly Intel: After-Hours Movers » 18:5807/1307/13/20
INMB, VNDA, FREQ, EW, BA, OSMT, ALT
Check out this evening's…
INmune Bio announces interim phase 1B data on XPro1595 in Alzheimer's » 16:1807/1307/13/20
INmune Bio reported…
INmune Bio reported clinical data demonstrating that its lead drug candidate, XPro1595, decreases neuroinflammation in patients with Alzheimer's disease. Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI. XPro1595 is a next-generation inhibitor of tumor necrosis factor that selectively neutralizes soluble TNF, an inflammatory cytokine implicated in Alzheimer's pathology, without affecting transmembrane TNF or the TNF receptors. Specifically, INmune compared biomarker data obtained from six patients treated with XPro1595 for 12 weeks with data from 25 Alzheimer's patients from the Alzheimer's Disease Neuroimaging Initiative that are part of a natural history database in patients with Alzheimer's. Over a 12-week period, whole brain inflammation increased by 5.1% in the ADNI patients compared to an increase of 1.7% and a decrease of 2.3% in patients treated weekly with 0.3mg/kg or 1.0mg/kg of XPro1595, respectively. A more detailed analysis revealed a 40.6% reduction in neuroinflammation in the Arcuate Fasciculus in patients treated with XPro1595. By contrast, the ADNI cohort had a 4.6% increase in Arcuate Fasciculus neuroinflammation.
|Over a month ago|
INmune Bio receives regulatory approval to initiate Phase 1 trial of INKmune » 09:0106/1106/11/20
INmune Bio announced that…
INmune Bio announced that the Medicines and Healthcare products Regulatory Agency has given approval to initiate a Phase I clinical trial of INKmune, a novel therapy to prime the patient's own NK cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome. This single center Phase I trial will be the first-in-man study using INKmune. Based on the current environment and timetable of its clinical site, INmune Bio is targeting the study initiation in the 2nd half of this year.
INmune Bio announces publication of review of innate immune cell potential » 09:0805/1905/19/20
INmune Bio announced…
INmune Bio announced publication of a review article: Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer in the journal Stem Cells Translational Medicine by May Sabry, PhD and Professor Mark Lowdell, PhD, co-founder and Chief Scientific Officer of INmune Bio, past vice-president (Europe) of the International Society of Cell & Gene Therapy and faculty professor at University College London. The article reviews the potential of harnessing cells of the innate immune system to treat cancer. This publication is one of the first to comprehensively review clinical trials of the common innate immune effector cells. It highlights the breadth of innate immunotherapy options and the global interest in harnessing this side of the immune system. Prof. Lowdell has been a leader in identifying how cancer evades innate immune surveillance by NK cells and how to overcome those resistance mechanisms to allow NK cells to attack the tumor.
INmune Bio announces upcoming milestones » 09:0805/1405/14/20
Report results of Phase 1…
Report results of Phase 1 XPro1595 in Alzheimer's Disease, expected to complete 2H 2020. Submit IND for Quellor for the prevention of complications of COVID-19 infection, expected in May 2020. Enroll first patient in Phase II Quellor program, targeting COVID-19 patients with complications from COVID19 as soon as possible. The following milestone timelines have been updated due to the ongoing COVID-19 pandemic. Enroll first patient in Phase II INB03 program, targeting trastuzumab resistant HER2+ breast cancer using INB03 as part of combination therapy, expected mid-2021. Enroll first patient in Phase II LIVNate for NASH, expected mid-2021. Enroll first patient in Phase I INKmune in High Risk MDS cancer, expected 2H20. Enroll first patient in Phase I INKmune in Ovarian cancer, expected mid-2021.
INmune Bio on track to report data in XPro1595 Phase 1 study in October 09:0705/1405/14/20